Variable | Value | Range | Reference |
---|---|---|---|
Probability of metachronous liver metastases if abnormal abdominal ultrasound | 0.85 | [0.80–0.95] | (4,18) |
Diagnostic imaging test performances for detection | |||
CT sensitivity | 0.98 | [0.90–0.99] | (7,16,19) |
CT specificity | 0.85 | [0.80–0.95] | (7,16,19) |
PET sensitivity | 0.90 | [0.85–0.99] | (16,17) |
PET specificity | 0.98 | [0.80–0.99] | (16,17) |
MRI sensitivity | 0.98 | [0.90–0.99] | (7,15) |
MRI specificity | 0.95 | [0.80–0.98] | (7,15) |
1st liver biopsy sensitivity | 0.85 | [0.70–0.95] | (14) |
2nd liver biopsy sensitivity | 0.99 | — | Experts |
1st and 2nd liver biopsy specificity | 1.00 | — | (14) |
Diagnostic test performances for assessing resectability | |||
CT sensitivity | 0.80 | [0.80–0.99] | (21,22) |
CT specificity | 0.90 | [0.60–0.95] | (21,22) |
PET sensitivity | 0.95 | [0.80–0.99] | (20) |
PET specificity | 0.95 | [0.85–0.99] | (20) |
MRI sensitivity | 0.85 | [0.80–0.99] | (21) |
MRI specificity | 0.95 | [0.80–0.95] | (21) |
Proportion of resectable metastases | 0.20 | [0.10–0.40] | (4) |
Clinical practices | |||
Frequency of use of PET after a patient is considered as nonresectable after CT | 0.10 | [0.00–0.80] | Experts |
Proportion of patients directed toward chemotherapy in case of extensive disease | 0.90 | — | Experts |
Proportion of patients directed toward symptomatic treatment in case of extensive disease | 0.10 | — | Experts |
Risks associated with surgery for cure | |||
Morbidity rate | 0.10 | — | (23,24) |
Mortality rate | 0.03 | — | (23,24) |
Life expectancy (y) | |||
Absence of recurrence (68-y-old individual) | 5.62 | — | ∗ |
Surgery for cure | 1.86 | — | ∗ |
Chemotherapy | 1.11 | — | ∗ |
Symptomatic treatment | 0.60 | ∗ |
*Burgundy Digestive Cancer Registry.
PET = 18F-FDG PET.